Onkologi DK’s Post

In this MEDtalk, Maria Bourlon presents the updated efficacy in the intention-to-treat population at 55-month median follow-up on the CheckMate 9ER phase 3 trial. The results show that the combination therapy with nivo+cabo continues to maintain meaningful long-term benefits in efficacy endpoints, such as progression-free survival, overall survival, and overall response rates. #Survival #Kidneycancer

In this MEDtalk, Maria Bourlon presents the updated efficacy in the intention-to-treat population at 55-month median follow-up on the CheckMate 9ER phase 3 trial. The results show that the combination therapy with nivo+cabo continues to maintain meaningful long-term benefits in efficacy endpoints, such as progression-free survival, overall survival, and overall response rates. #Survival #Njurcancer

Learn the importance of multidisciplinary workup and management of respiratory symptoms and insufficiency in this case study about a patient w renal cell carcinoma by Faiz et al. https://lnkd.in/eGCRykCn #immunotherapy #ICIs #JIPO

This 55-month median follow-up of the CheckMate 9ER study on efficacy in the intention-to-treat population reinforces nivolumab plus cabozantinib as standard first-line therapy for advanced renal cell carcinoma. #KidneyCancer #RenalCellCarcinoma #FirstLineTherapy

Test your knowledge of renal cell carcinoma treatment with our interactive Clinical Case Challenge | Managing Adverse Events Associated With Novel Combination Therapies in RCC | 0.25-hour CME/CE | #MedEd #cme #renalcellcarcinoma | https://bit.ly/47WaJBT

This 55-month median follow-up of the CheckMate 9ER study on efficacy in the intention-to-treat population reinforces nivolumab plus cabozantinib as standard first-line therapy for advanced renal cell carcinoma. #KidneyCancer #RenalCellCarcinoma #FirstLineTherapy

Test your knowledge of renal cell carcinoma treatment with our interactive Clinical Case Challenge | Managing Adverse Events Associated With Novel Combination Therapies in RCC | 0.25-hour CME/CE | #MedEd #cme #renalcellcarcinoma | https://bit.ly/47WaJBT

Test your knowledge of renal cell carcinoma treatment with our interactive Clinical Case Challenge | Managing Adverse Events Associated With Novel Combination Therapies in RCC | 0.25-hour CME/CE | #MedEd #cme #renalcellcarcinoma | https://bit.ly/47WaJBT

Test your knowledge of renal cell carcinoma treatment with our interactive Clinical Case Challenge | Managing Adverse Events Associated With Novel Combination Therapies in RCC | 0.25-hour CME/CE | #MedEd #cme #renalcellcarcinoma | https://bit.ly/47WaJBT

My case of the day on #Radiopaedia Wunderlich syndrome with #pseudoaneurysm due to renal #angiomyolipoma rupture A spontaneous non-traumatic perinephric haemorrhage with acute flank pain, flank mass feeling, and hypovolaemic shock is known as Wunderlich syndrome. It can be due to neoplastic aetiologies such as angiomyolipoma and renal cell carcinoma rupture or non-neoplastic causes like vasculitis, AVM, and AVF rupture. The process is rarely complicated, with a pseudoaneurysm formation that should be reported in detail. See the full case: https://lnkd.in/gqn7XscE